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ARTICLE
A role for Tau protein in maintaining ribosomal
DNA stability and cytidine deaminase-deﬁcient cell
survival
Elias Bou Samra1,2,3, Géraldine Buhagiar-Labarchède 1,2,3, Christelle Machon4,5, Jérôme Guitton4,6,
Rosine Onclercq-Delic 1,2,3, Michael R. Green 7, Olivier Alibert 8, Claude Gazin8, Xavier Veaute 9
& Mounira Amor-Guéret 1,2,3
Cells from Bloom’s syndrome patients display genome instability due to a defective BLM and
the downregulation of cytidine deaminase. Here, we use a genome-wide RNAi-synthetic
lethal screen and transcriptomic proﬁling to identify genes enabling BLM-deﬁcient and/or
cytidine deaminase-deﬁcient cells to tolerate constitutive DNA damage and replication
stress. We found a synthetic lethal interaction between cytidine deaminase and microtubule-
associated protein Tau deﬁciencies. Tau is overexpressed in cytidine deaminase-deﬁcient
cells, and its depletion worsens genome instability, compromising cell survival. Tau is
recruited, along with upstream-binding factor, to ribosomal DNA loci. Tau downregulation
decreases upstream binding factor recruitment, ribosomal RNA synthesis, ribonucleotide
levels, and affects ribosomal DNA stability, leading to the formation of a new subclass of
human ribosomal ultraﬁne anaphase bridges. We describe here Tau functions in maintaining
survival of cytidine deaminase-deﬁcient cells, and ribosomal DNA transcription and stability.
Moreover, our ﬁndings for cancer tissues presenting concomitant cytidine deaminase
underexpression and Tau upregulation open up new possibilities for anti-cancer treatment.
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Every life form delivers its genetic material to the next gen-eration. However, a myriad of alterations can underminethe integrity of this process, thereby favoring genomic
instability, which can drive diseases, premature aging and
tumorigenesis1.
Cells from Bloom’s syndrome (BS) patients display high levels
of genomic instability. BS belongs to a group of rare human
genetic diseases with a particularly high rate of spontaneous
chromosome abnormalities2, 3. BS results from mutations of
both copies of the BLM gene, which encodes a 3ʹ–5ʹ DNA
helicase4 and is characterized by a high incidence of sister
chromatid exchanges2, 4, 5 and strong predisposition to cancers6.
BS cells suffer from replication stress and chromosome segrega-
tion defects, including an abnormally high frequency of ultraﬁne
anaphase bridges (UFBs). We have shown that BLM deﬁciency
leads to the downregulation of cytidine deaminase (CDA), an
enzyme of the pyrimidine salvage pathway7. CDA catalyzes the
hydrolytic deamination of cytidine (C) and deoxycytidine (dC) to
uridine (U) and deoxyuridine (dU), respectively8. The imbalance
in the nucleotide pool resulting from the CDA defect, either in
BLM-deﬁcient BS cells or BLM-proﬁcient HeLa cells, reproduced
several aspects of the genetic instability associated with BS
condition7, 9. These data suggest that BS cells lacking both BLM
and CDA, and CDA-deﬁcient HeLa cells have developed
mechanisms for tolerating endogenous DNA damage and repli-
cation stress.
In this study, we aimed to identify interactors enabling
BLM-deﬁcient and/or CDA-deﬁcient cells to survive despite
constitutive genetic instability, thereby contributing to carcino-
genesis. We performed a genome-wide shRNA screen with a BS
cell line, and its counterpart in which BLM function was
corrected. The BS cells were likely to display higher levels of
cell lethality due to the depletion of the microtubule-associated
protein Tau. This lethality was observed in various CDA-deﬁcient
cells, but not in BLM-deﬁcient cells expressing CDA, revealing a
synthetic lethal interaction between Tau and CDA deﬁciencies.
Multiple functions have been attributed to Tau, based on its
broad distribution within cells. In particular, nuclear Tau
was shown to preserve DNA integrity in neurons, under both
physiological and DNA-damaging conditions10, 11. Here, we
observe the corecruitment of Tau and upstream binding factor
(UBTF) to the nucleolar organizing regions (NORs), and ﬁnd that
Tau silencing reduces the recruitment of UBTF to ribosomal
DNA (rDNA) repeats, thereby impairing rDNA transcription.
Tau depletion also associates with lower intracellular ribonu-
cleotide concentrations, consistent with the observed decrease in
rDNA transcription. Moreover, the staining pattern for mitotic
Tau foci reveals the presence of a new class of human UFBs
extending from rDNA repeats. These rDNA-associated UFBs are
particularly abundant in situations of nucleotide pool distortion
and replication challenge. Finally, Tau depletion is sufﬁcient to
cause genomic instability, and its coupling with CDA deﬁciency
aggravates this instability. These results reveal a function for Tau
in rDNA metabolism, and indicate that Tau is critical for the
survival of CDA-deﬁcient cells, through its contribution to the
safeguarding of genome integrity.
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Fig. 1 RNAi-based synthetic interaction screen. a Schematic representation of the genome-wide shRNA-screening procedure. Brieﬂy, the screening
involved four steps: (1) transduction of BS-Ctrl(BLM) and BS-BLM cells with a library of pooled lentiviral human shRNAs; (2) isolation of genomic DNA
from cell populations 40 h or 20 days post-infection (p.i.); (3) PCR ampliﬁcation of isolated genomic DNA; (4) quantiﬁcation of shRNA populations by
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Results
RNAi-synthetic interaction screen in BS cells. We searched for
genes potentially required for the viability and proliferation of BS
cells, by conducting a genome-wide RNAi screen with a human
shRNA library comprising ∼60,000 shRNAs directed against
∼27,000 human genes12. We screened an isogenic pair of
GM8505B-derived BS cell lines in parallel. The ﬁrst line lacked
the BLM protein and therefore displayed strong downregulation
of CDA expression (BS-Ctrl(BLM), BLM−/CDA−), whereas the
helicase defect of the second line was functionally corrected
by stable transfection with the BLM cDNA, which also restored
CDA expression (BS-BLM, BLM+/CDA+) (Supplementary Fig. 1).
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This screen might, therefore, allow the identiﬁcation of genes
required for the survival of BLM-deﬁcient and/or CDA-deﬁcient
cells. An overview of the workﬂow is summarized in Fig. 1a. We
identiﬁed 959 targets in our primary screen as candidate synthetic
lethal genes in BS cells (Supplementary Data 1).
Gene ontology (GO) analyses of hits with DAVID13 revealed
enrichment in a group of 12 terms associated with nucleotide
binding (Enrichment score= 2.86, Supplementary Table 1). The
most signiﬁcant GO biological process term was “purine
nucleotide biosynthesis” (P= 8.79×10−4, −log2(P)= 10.15;
Modiﬁed Fisher exact test; Fig. 1b, Supplementary Table 2).
The importance of this cellular process was strongly reﬂected in
the GO molecular function terms identiﬁed as enriched, which
included ATP binding (P= 5.84×10−4, −log2(P)= 10.74; Mod-
iﬁed Fisher exact test) and ribonucleotide binding (P= 9.05×10−4,
−log2(P)= 10.11; Modiﬁed Fisher exact test; Fig. 1b, Supplemen-
tary Table 3). Other DAVID GO terms associated with
microtubule cytoskeleton and organization were among the
top clusters observed in the group of synthetic lethal genes
(P= 5.31×10−3, −log2(P)= 7.56; Modiﬁed Fisher exact test;
Fig. 1b, Supplementary Table 2). The identiﬁcation of these
genes presumably reﬂects the essential role of many cytoskeletal
proteins in BS cell viability.
We limited the number of candidates in our primary screen, by
cross-referencing these data with a list of genes upregulated in
BS-Ctrl(BLM) relative to BS-BLM cells. We studied mRNA levels
with the Affymetrix U133 Plus 2.0 Arrays previously used for
these cell lines7 (refer to the Methods section for link). Signiﬁcant
differences in mRNA levels were detected, with an absolute
expression ratio difference of ≥1.5 and a P< 0.05 (Moderated
t-test). On the basis of these criteria, 692 genes were considered to
be upregulated in BS cells relative to controls (Fig. 1c,
Supplementary Data 2). Twenty-one of these genes (3%) were
identiﬁed in the synthetic lethal screen (Supplementary Table 4).
GO analysis was performed on this group of genes. Further
enrichment in the biological process term “regulation of
cytoskeleton organization” (P= 8.44×10−3, enrichment = 19.89;
Modiﬁed Fisher exact test) and the cellular component term
“cytoskeletal part” (P= 3.33×10−2, enrichment= 4.88; Modiﬁed
Fisher exact test, Supplementary Table 5) was observed.
Three genes corresponding to these enriched terms were
highly represented: CCDC88A, CAPG, and MAPT (Supplemen-
tary Table 5). CCDC88A and CAPG encode actin-binding
proteins that play a role in cytoskeleton remodeling and cell
migration14–16; MAPT encodes Tau, a microtubule-binding
protein that stimulates microtubule assembly by polymerizing
with tubulin, thereby participating in cytoskeleton organization
and integrity17. Strong expression of these three genes has been
observed in various tumors, and has been reported to promote
metastasis and increase the invasiveness of tumor cells18–20.
In this study aiming to identify key players favoring the tolerance
of constitutive genetic instability in BS cells, we searched for
speciﬁc cytoskeletal genes likely to favor the maintenance of
genome integrity. MAPT was the only one of these three genes
already known to have a DNA-protecting function. Tau has been
shown to protect neuronal nuclear DNA from heat stress-induced
damage, and to promote chromosome stability10, 11, 21. We thus
focused on Tau in subsequent experiments.
Tau silencing reduces the survival of CDA-deﬁcient cells.
In our transcriptomic data, Tau mRNA levels in BS cells were
found to be twice those in controls (Supplementary Table 4).
By examining microarray expression data for BLM-depleted or
non-speciﬁc shRNA-treated isogenic control ﬁbroblasts available
under accession no. GSE5450222, we also found that Tau was
signiﬁcantly upregulated in BLM-depleted cells relative to control
cells (Fold-change= 1.45, P= 7.63×10−4; Moderated t-test; Sup-
plementary Fig. 2a, b), supporting our ﬁndings. The over-
expression of Tau in BS cells was conﬁrmed by reverse
transcription quantitative PCR (RT-qPCR) and western blotting
(WB) (Fig. 2a–c). We used Tau-5 monoclonal antibody, which
detects all Tau proteins, regardless of their phosphorylation state
(Fig. 2b). As we planned to investigate the nucleolar distribution
of Tau in subsequent experiments and the Tau-5 antibody is not
suitable for Tau nucleolar immunostaining, we also tested
the only Tau antibody for which nucleolar staining has been
reported23, the Tau-1 antibody (Fig. 2c). This antibody recognizes
the unphosphorylated Tau epitope Ser195-202. BLM expression
reduced Tau mRNA levels by 59%, (Fig. 2a) and the amounts
of protein detected by Tau-5 and Tau-1 by 28 and 36.5%,
respectively (Fig. 2d, e).
For validation of the apparent synthetic lethality interaction
between Tau and BLM and/or CDA deﬁciencies, we transfected
BS-Ctrl(BLM) and BS-BLM cells with a pool of four Tau-targeting
siRNAs. Then, 72 h after transfection, we assessed changes
in MAPT mRNA and Tau protein levels in BS-Ctrl(BLM) and
BS-BLM cells by RT-qPCR and WB, respectively (Fig. 2f, g and
Supplementary Fig. 2c–e). Both cell lines were monitored for
colony formation. Tau downregulation in BLM-complemented
cells did not affect the clonal growth (Fig. 2h). However, a
45–48% decrease in Tau protein levels resulted in a 60% decrease
in the colony-forming ability of BLM-null cells (Fig. 2g, h and
Supplementary Fig. 2e), conﬁrming the observations made in the
primary shRNA screen.
BLM deﬁciency decreases CDA levels in BS cells7. We
investigated whether the synthetic lethal phenotype observed on
Tau downregulation was due to CDA deﬁciency per se. We
performed colony formation assays in BS-CDA (BLM−/CDA+)
and CDA-deﬁcient cells (BS-Ctrl(CDA), BLM−/CDA−) after Tau
Fig. 2 Tau silencing reduces the survival of CDA-deﬁcient cells. a MAPT mRNA levels determined by RT-qPCR in BS-Ctrl(BLM) and BS-BLM cells. b, c BLM
and Tau levels determined by western blotting in BS-Ctrl(BLM) and BS-BLM cells using BLM and either Tau-5 (b) or Tau-1 (c) antibodies. d, e Tau
protein quantiﬁcation for Tau-5 (d) and Tau-1 (e) immunoreactivity. The β-actin signal was used as the control. The results are normalized against those
for BS-BLM, which were set to 1. f–k Cells were ﬁrst transfected with either non-targeting or Tau siRNA. After 24 h, cells were again transfected with the
indicated siRNAs. Two days after the second round of transfection, the cells were collected for western blotting f, i, or were plated, in a serial dilution
series, in 12-well plates. Ten to 12 days later, colonies were ﬁxed and stained with crystal violet. Non-targeting siRNA was used as a control, with values set
to 1 h, k. g, j Tau protein quantiﬁcation after Tau-targeting siRNA depletion. l MAPT mRNA and m Tau protein levels determined in HeLa-Ctrl(Tau) and
HeLa-shTau cells. n, o HeLa-Ctrl(Tau) and HeLa-shTau cells were ﬁrst transfected with the indicated siRNAs. After 24 h, cells were again transfected with
the same siRNAs. Two days after the second round of transfection, cells were collected for western blotting (n), or were plated, in a serial dilution series, in
12-well plates. Seven days later, colonies were ﬁxed and stained with crystal violet. Non-targeting siRNA was used as a control, with the values obtained set
to 1 (o). For qPCR, the mean value for 3 independent experiments is represented as a fold-change. B2M, β-actin, and TBP were used as housekeeping genes
for qPCR normalization. For western blots, β-actin was used as a loading control. Each data bar is the mean of at least three independent experiments
performed in triplicate. Error bars represent± SEM. The signiﬁcance of differences was assessed in two-tailed paired Student’s t-tests. ***P< 0.0005,
**P< 0.005, *P< 0.05, NS not signiﬁcant
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depletion (Fig. 2i–k and Supplementary Fig. 2f, g). The stable
expression of CDA in BS cells reduced Tau protein levels by
35 and 39%, as shown with the Tau-5 and Tau-1 antibodies,
respectively (Fig. 2i, j and Supplementary Fig. 2f, g), suggesting
that high levels of Tau expression in BS cells probably results
from CDA deﬁciency rather than from BLM deﬁciency per se.
CDA expression in BLM-deﬁcient cells was sufﬁcient to rescue
the inhibition of clonal growth (Fig. 2k). Thus, it is CDA
depletion, rather than a lack of BLM, that induces synthetic
lethality in the absence of Tau. For conﬁrmation of these
results, we knocked down Tau levels in HeLa cells (HeLa-shTau)
(Fig. 2l, m and Supplementary Fig. 2h). Tau depletion had no
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impact on the clonal survival of either of the isogenic cell lines
(Supplementary Fig. 2i). In these cells, BLM or CDA levels were
downregulated with speciﬁc siRNAs (Fig. 2n). We also transiently
depleted Tau from HeLa-shTau cells with a pool of siRNAs
directed against sequences other than that targeted by the shRNA
construct, to obtain better extinction of Tau mRNA and protein
levels (Supplementary Fig. 2j, k and Fig. 2m). An analysis of
colony-forming ability showed that the silencing of CDA, but not
of BLM, impaired the clonal growth of Tau-deﬁcient cells by
~30% relative to controls (Fig. 2o). Our data demonstrate that
Tau depletion is synthetic lethal with CDA deﬁciency.
Tau interacts with rDNA and regulates rDNA transcription.
To decipher the molecular basis of the synthetic lethal interaction
between CDA and Tau deﬁciencies, we investigated the potential
role of Tau in maintaining genome stability in non-neuronal
cells. We thus analyzed the impact of Tau knockdown on
phosphorylated H2AX (γ-H2AX) levels, 53BP1 focus formation
and UFB frequency (Fig. 3a–e). Tau silencing increased γ-H2AX
levels, as revealed by WB and the high percentage of cells with
more than 20 γ-H2AX foci (Fig. 3b, c). Tau knockdown also
generated a signiﬁcantly higher frequency of 53BP1 foci at nuclei,
and resulted in a signiﬁcant increase in UFB frequency, consistent
with the existence of endogenous DNA damage and replication
stress in Tau-deﬁcient cells (Fig. 3d, e).
Based on previous reports indicating a role for nuclear
Tau protein in neuronal DNA and RNA protection10, 11,
we assessed the sensitivity of non-neuronal parental and
Tau-deﬁcient HeLa cells to various cytotoxic agents in viability
assays. Tau-deﬁcient cells were as sensitive as parental cells to the
catalytic inhibitor of topoisomerase II ICRF-159 or the inhibitor
of RNA polymerase II α-amanitin (Supplementary Fig. 3a, b),
72 h after treatment. However, Tau silencing resulted in mild
sensitivity to the B-family DNA polymerases inhibitor aphidicolin
(APH), the topoisomerase I inhibitor camptothecin (CPT)
and the ribonucleotide reductase inhibitor hydroxyurea (HU)
(~1.5-fold; Fig. 3f–h), and a marked increase in sensitivity to the
speciﬁc RNA polymerase I inhibitor CX-5461 (~3.5-fold; Fig. 3i),
suggesting a role for Tau in ribosomal RNA (rRNA) transcrip-
tion. As described above, CDA-deﬁcient BS cells overexpressed
Tau. Consistent with this ﬁnding, HeLa cells with physiological
levels of BLM but a stable depletion of CDA also overexpressed
Tau (Fig. 3j). We subjected these cells to drug sensitivity assays.
CDA-deﬁcient cells and control cells had similar sensitivities to
ICRF-159, α-amanitin, and APH (Supplementary Fig. 3c–e).
After treatment with CPT or HU, CDA-deﬁcient cells became
slightly less or more sensitive than control cells, respectively
(~1.5-fold; Supplementary Fig. 3f, g). By contrast, CDA depletion
led to a 3.5-fold increase in resistance to CX-5461 (Fig. 3k),
probably due to Tau overexpression. This greater resistance
of CDA-deﬁcient cells to CX-5461 treatment was inversely
correlated with the greater susceptibility of Tau-depleted cells to
the same treatment. Collectively, these ﬁndings provide further
support for a role for Tau in rRNA transcription.
Within the nucleus, Tau has been shown to localize speciﬁcally
to the ﬁbrillary regions of interphase nucleoli and the NORs23, 24.
We examined Tau nucleolar localization by the co-immunostain-
ing of BS cells for the RNA polymerase I regulatory protein
UBTF. UBTF is a key component of the pre-initiation complex
(PIC) of rRNA transcription, mediating the recruitment of RNA
polymerase I to rDNA promoter regions25. We found that, during
interphase, Tau was co-localized with UBTF, in discrete foci
within the nucleolus. When the cells entered prometaphase, Tau
and UBTF formed paired foci linked to the NORs on acrocentric
chromosomes. These foci persisted throughout prophase and
metaphase, subsequently segregating symmetrically during early,
mid and late anaphase (Fig. 3l). The Tau-1 antibody efﬁciently
labels nucleolar mitotic Tau by detecting an unphosphorylated
Tau epitope, but it is widely accepted that Tau phosphorylation
increases during mitosis in neuronal and non-neuronal cells26.
We therefore examined interphase and mitotic BS cells by
immunoﬂuorescence microscopy with two phosphorylation-
dependent antibodies sensitive to phosphorylation of the
Thr231 and Ser396 epitopes. As previously reported, very low
levels of Tau phosphorylation were detected in interphase BS
cells, whereas Tau became highly phosphorylated during mitosis
(Supplementary Fig. 3h, i). In mitotic cells, immunoreactivity
with the P-Thr231 antibody was observed at centrosomes during
prometaphase. This immunoreactivity decreased during meta-
phase and anaphase, and was seen again in the midbody region
during telophase (Supplementary Fig. 3h). Immunoreactivity with
the P-Ser396 antibody was also localized to the midbody region in
anaphase and telophase cells (Supplementary Fig. 3i). Thus, in BS
cells, Tau displays low levels of phosphorylation in interphase
cells, but becomes highly phosphorylated during mitosis, as
reported in neuronal cells26. However, none of the tested
phosphorylation-dependent antibodies localized to the nucleolus
or to the NORs.
The co-localization of Tau with UBTF to the NORs led us to
investigate whether Tau interacted with rDNA. We performed
chromatin immunoprecipitation (ChIP)-qPCR with primers
covering the different regions of the rDNA gene (Fig. 3m). One
repeat contains ∼13.3 kb of sequence encoding the 18 S, 5.8 S, and
28 S rRNAs and a non-coding intergenic spacer (IGS) containing
an enhancer, a spacer promoter and the core promoter of the
Fig. 3 Tau interacts with rDNA and regulates rDNA transcription. a Immunoﬂuorescence microscopy showing γ-H2AX (red) and 53BP1 (green) labeling.
Merged images in the right panel. Scale bar: 5 µm. b γ-H2AX and Tau-1 protein levels assessed by immunoblotting. GAPDH was used as a loading control. c,
d Cells were immunostained with antibodies against γ-H2AX and 53BP1. At least 400 cells were acquired, and foci counted. The number of cells (n) is
indicated. e Mean number of PICH-coated UFBs per anaphase (at least 200 anaphase cells per condition). The signiﬁcance of differences was assessed in
two-tailed unpaired Student’s t-tests. f–i, k Cells were exposed, for 72 h, to aphidicolin (f), camptothecin (g), hydroxyurea (h), and CX-5461 (i, k). Each
data point is the mean of at least three independent experiments in triplicate. j BLM, Tau-5 and CDA protein levels. β-actin was used as a loading control.
l Immunoﬂuorescence microscopy showing UBTF (red) and Tau-1 (green) co-localization in BS cells. Merged images (yellow) in the bottom panel. Scale bar:
5 µm. m Schematic representation of a human rDNA repeat (upper panel). Chromatin immunoprecipitation (ChIP) with Tau-1, UBTF and IgG antibodies in
BS cells (lower panel). DNA was quantiﬁed by qPCR with primer pairs covering the rDNA repeat. Their approximate positions relative to the transcription
start site (TSS) are indicated on the x axis. Data are the means from three independent experiments. n, o Endogenous pre-rRNA (45 S) levels were
monitored by qPCR. B2M, β-actin, and TBP were used as housekeeping genes for normalization. The signiﬁcance of differences was assessed in two-tailed
paired Student’s t-tests. p, q ChIP with Tau-1 (p), UBTF (q), and IgG (p, q) antibodies. Results are obtained as described in (m). r, sMeasurements of pools
of NMPs and NTPs. Values of peak surface areas ratios between the endogenous nucleotide and its internal standard are shown. The data are the means of
9 independent measurements corresponding to three independent experiments performed in triplicate. The signiﬁcance of differences was assessed
in Mann–Whitney tests. For IF, DNA was visualized by DAPI staining (blue or white). Error bars represent± SEM from three independent experiments.
***P< 0.0005, **P< 0.005, *P< 0.05
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adjoining rDNA repeat27, 28. For conﬁrmation of the speciﬁcity of
the assay, we performed ChIP-qPCR with UBTF, which is known
to interact with the rDNA locus29, 30. The endogenous occupancy
proﬁle obtained for Tau closely resembled that for UBTF. Tau
was speciﬁcally associated with the promoter and the transcribed
region of the rDNA, but not with the IGS (Fig. 3m). These results,
which were also validated in human embryonic kidney HEK-
293T cells (Supplementary Fig. 3j), suggest that Tau may
be involved in the regulation of rRNA synthesis. We measured
pre-rRNA levels in control cells and in cells with stable or
transient Tau depletions. Control qPCR assays on RNA samples
were carried out in parallel, in the absence of reverse
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transcriptase, to check that the ampliﬁcation observed did
not result from the presence of contaminating genomic DNA.
RT-qPCR analysis revealed that Tau depletion signiﬁcantly
decreased rDNA transcription levels (Fig. 3n). In addition,
CDA-deﬁcient cells had higher levels of pre-rRNA synthesis
(Fig. 3o), correlated with higher levels of Tau expression (Fig. 3j).
Taken together, these data suggest that Tau expression upregu-
lates rRNA synthesis. As Tau expression was correlated with
pre-rRNA levels, we investigated the mechanism by which the
decrease in Tau levels decreased 45 S pre-rRNA synthesis, by
performing ChIP-qPCR assays to analyze the effect of Tau
downregulation on UBTF recruitment to rDNA repeats. We
found that Tau downregulation halved nucleolar Tau binding to
rDNA repeats in Tau-depleted cells, as expected (Fig. 3p).
Moreover, Tau downregulation also signiﬁcantly reduced the
recruitment of UBTF to the promoter regions of rDNA units
(Fig. 3q) without affecting total UBTF protein levels (Supple-
mentary Fig. 3k). Thus, Tau regulates rRNA synthesis through
the recruitment of UBTF to rDNA promoters.
Our results showing UBTF and Tau co-localization in
nucleolar regions and to rDNA repeats led us to hypothesize
that, like Tau deﬁciency, UBTF deﬁciency might present a
synthetic lethal interaction with CDA deﬁciency, albeit one not
detected in the RNAi screen. We therefore investigated whether
UBTF downregulation impaired the survival of CDA-deﬁcient
cells. We transfected BS-Ctrl(BLM) and BS-BLM cells with UBTF-
targeting siRNAs (Supplementary Fig. 3l). Then, 48 h after
transfection, both cell lines were monitored for colony formation.
UBTF downregulation had no effect on clonal growth in either
cell line (Supplementary Fig. 3m), demonstrating an absence of
synthetic lethal interaction between UBTF and BLM and/or CDA
deﬁciencies.
As rRNA synthesis accounts for 35–60% of all transcription31,
we hypothesized that the observed inhibition of pre-rRNA
synthesis might be linked to a decreased in the intracellular
concentration of ribonucleotides. We therefore evaluated the sizes
of the nucleotide pools in parental and Tau-null cells. Liquid
chromatography tandem mass spectrometry (LC–MS/MS)
analyses showed that Tau knockdown markedly decreased
intracellular levels of UMP, GMP, CMP and AMP relative to
controls (Fig. 3r and Supplementary Fig. 3n). The UTP, GTP,
CTP and ATP pools were also smaller in Tau-deﬁcient cells
(Fig. 3s and Supplementary Fig. 3o). However, Tau depletion
did not affect intracellular levels of purine and pyrimidine
deoxynucleotide monophosphates (dNMPs) and triphosphates
(dNTPs), demonstrating that the genetic instability observed in
Tau-deﬁcient cells did not result from disequilibrium of
the dNMP or dNTP pools (Supplementary Fig. 3p–s). These
results demonstrate that ribonucleotide monophosphate and
triphosphate levels are low in Tau-deﬁcient cells, consistent with
our ﬁnding of a signiﬁcant decrease in rDNA transcription after
Tau depletion (Fig. 3n).
Tau loss alters genetic integrity of rDNA and CDA−/− cells.
Different types of UFBs have been described in human cells,
extending from centromeres (C-UFBs), common fragile sites
(CFS-UFBs), or telomeres (T-UFBs)32–34. UFBs can be visualized
by detection of the helicase-like protein, PICH (Plk1-interaction
checkpoint “helicase”)35 which decorates UFBs along their entire
length. Other proteins, such as BLM, can also be recruited to
bridges but only to pre-existing PICH-coated UFBs34. Thus, the
total UFB population can be detected only by staining for PICH.
Nielsen and Hickson reported that rDNA marks a novel class
of UFBs in chicken cells36, but did not determine whether
these DNA structures were also present in human cells. We
investigated whether human rDNA loci were prone to ultraﬁne
anaphase bridging, by co-immunostaining rDNA loci and UFBs,
with anti-Tau-1 and anti-PICH antibodies, respectively. Given
the close proximity of rDNA loci and centromeres on human
acrocentric chromosomes, we also labeled centromeres with an
antibody against human kinetochore/centromere-speciﬁc CREST
serum37 to distinguish between C-UFBs and Tau-positive UFBs.
We found that mitotic Tau foci were localized at the termini
of UFBs, in a pattern similar to that observed for C-UFBs or
CFS-UFBs (Fig. 4a, b and Supplementary Fig. 4a, b). In both cell
lines, Tau-positive UFBs were rare, accounting for only ~3–6% of
all bridges (Fig. 4c). We showed above that Tau co-localizes with
UBTF on the NORs during mitosis, suggesting that Tau-positive
UFBs might also display positive staining for UBTF. We
thus explored whether UBTF also hung on to the ends of
UFBs and evaluated the prevalence of UBTF-positive UFB
events. As expected, UBTF-positive UFBs were detected, with a
prevalence similar to that of Tau-positive UFBs (Supplementary
Fig. 4c, d), indicating that this new subset of UFBs does indeed
extend from rDNA clusters facing replication disturbance. These
results reveal the existence of a new class of UFBs in human cells,
rDNA-associated UFBs, hereafter referred to as R-UFBs.
We investigated the effect of CDA loss on the frequency of
R-UFBs. The mean number of R-UFBs per anaphase cell was
signiﬁcantly higher in CDA-defective cells than in control cells
(Fig. 4d). We determined R-UFB frequency after the treatment of
cells with tetrahydrouridine (THU), a potent CDA inhibitor38, or
with dC, which is known to increase the intracellular concentra-
tions of dC and dCTP7, 9, to mimic the effects of CDA deﬁciency.
THU or dC treatment had no effect on the prevalence of R-UFBs
in CDA-deﬁcient cells, but signiﬁcantly increased the number of
R-UFBs in CDA-proﬁcient cells (Fig. 4e and Supplementary
Fig. 4 Tau loss alters genetic integrity of rDNA and CDA−/− cells. a, b Representative immunoﬂuorescence (IF) z‐projection images showing paired Tau
foci (green) linked by PICH-positive UFBs in BS (a) and HeLa (b) anaphase cells. Scale bar: 5 µm. DNA was visualized by DAPI staining (white). Centromeres
were stained with CREST serum (blue) and UFBs were stained with PICH antibody (red). In the enlarged images, Tau foci at the extremities of UFBs are
indicated by yellow arrows. c Mean number of total and Tau-positive UFBs per anaphase cell. d, f Mean number of R-UFBs per anaphase cell in untreated
cell lines. e Relative number of R-UFBs per anaphase cell in BS-Ctrl(BLM) and BS-BLM cells left untreated or treated with 100 µM tetrahydrouridine (THU)
for 2 × 48 h or 1 mM of deoxycytidine (dC) for 10 h. g Mean number of R-UFBs per anaphase cell in BS-Ctrl(BLM) and BS-BLM cells left untreated or treated
with 0.4 µM aphidicolin (APH) or 1 µM ICRF-159 for 24 h. The results were normalized against those for control conditions (mock), which were set to 1. h
HeLa-Ctrl(Tau) and HeLa-shTau cells were ﬁrst transfected with either non-targeting or CDA siRNA. After 48 h, cells were again transfected with the
indicated siRNAs. Three days after the second round of transfection, cells were collected for western blotting, with GAPDH as the loading control (h),
or were immunostained with antibody against γ-H2AX or 53BP1 (i, j). At least 1500 cells were acquired by wide-ﬁeld microscopy, and γ-H2AX (i) or
53BP1 (j) foci were counted. The number of cells (n) for each condition is indicated. k, l Cells were immunostained with antibodies against PICH and UBTF,
and the mean numbers of total and rDNA-associated UFBs per anaphase cell were monitored. For IF experiments, DNA was counterstained with DAPI.
For UFB counting, at least 200 cells were acquired by wide-ﬁeld microscopy. For all data bars, error bars represent± SD from at least three
independent experiments. The signiﬁcance of differences was assessed in two-tailed unpaired Student’s t-tests. ***P< 0.0005, **P< 0.005, *P< 0.05,
NS not signiﬁcant
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Fig. 4e), demonstrating the crucial role of CDA proﬁciency, and
the resulting balanced pyrimidine nucleotide pool, in the
prevention of R-UFB formation.
Like CDA deﬁciency, Tau deﬁciency favors UFB formation
(Fig. 3e). We therefore investigated the possible impact of Tau
deﬁciency on R-UFB frequency. UBTF was used as a marker of
rDNA loci in cells lacking Tau. Immunostaining assays showed
that Tau-depleted cells had more UBTF-associated UFBs than
control cells (Fig. 4f), indicating a role for Tau in preventing
R-UFB formation.
Exposure to APH induces the expression of fragile sites in the
genome33, 39. rDNA clusters have been shown to be sensitive to
APH and are thought to behave as fragile sites40–42. We therefore
investigated whether R-UFB events were affected by exposure
to APH. As expected, APH treatment signiﬁcantly increased
the numbers of CFS-associated UFBs in CDA-proﬁcient and
CDA-deﬁcient cells, as shown by FANCD2 immunostaining
(Supplementary Fig. 4f, g). Similarly, R-UFB frequency was
also signiﬁcantly increased by the APH treatment of these
cells (Fig. 4g and Supplementary Fig. 4h). A previous study
demonstrated that the treatment of chicken DT-40 cells with
an inhibitor of topoisomerase IIα increased the number of
R-UFBs43, but we observed no induction of R-UFBs after
ICRF-159 treatment in two independent human cell models
(Fig. 4g and Supplementary Fig. 4h). By contrast, the frequency of
C-UFBs, as revealed by CREST staining, was signiﬁcantly higher
after this treatment, as previously reported33 (Supplementary
Fig. 4i, j). Thus, the replication stress resulting from CDA
depletion or the partial inhibition of replication favors ribosomal
ultraﬁne anaphase bridging.
Finally, we explored how simultaneous depletion of the
CDA and Tau proteins led to a synthetic lethal interaction. We
therefore monitored γ-H2Ax and 53BP1 foci frequency, and UFB
formation after simultaneous Tau and CDA downregulation.
As expected, in control cells, the depletion of CDA alone led to
increases in γ-H2AX levels, the number of 53BP1 foci, and the
prevalence of both total UFBs and R-UFBs (Fig. 4h–l). Moreover,
CDA depletion led to an increase in Tau mRNA and protein
levels (Fig. 4h and Supplementary Fig. 4k). Finally, down-
regulating CDA expression in Tau-deﬁcient cells led to a marked
shift towards the presence of large numbers of γ-H2AX and
53BP1 foci in nuclei and an increase in the numbers of total and
rDNA-associated UFBs (Fig. 4h–l). Thus, the simultaneous
depletion of both proteins aggravated genome instability.
CDA and MAPT levels are negatively correlated in cancer. BS
cells and CDA-deﬁcient HeLa cells overexpressed Tau, as
described above. Tau levels have been reported to increase in
certain subtypes of breast cancer44. We have recently shown that
CDA expression is downregulated in ~60% of cancer cells and
tissues45. We therefore investigated the possible correlation
between CDA loss and Tau overexpression in physiological
conditions. We did this by in silico analyses of MAPT and CDA
expression levels in several cohorts of cancer cell lines and tissues.
An analysis of two cohorts of cancer cell line samples45, 46 showed
that MAPT levels were signiﬁcantly higher in samples with low
CDA levels, and vice versa (Fig. 5a, b). We then compared CDA
andMAPT mRNA levels in gene expression data sets for different
tissue samples47–49 (Supplementary Data 3–7). The negative
correlation between CDA and MAPT transcript levels was
signiﬁcant in cancers of several tissues, including breast cancer
(Fig. 5c), papillary, and clear cell kidney carcinomas (Fig. 5d, e),
prostate adenocarcinoma (Fig. 5f), and pheochromocytoma and
paraganglioma (Fig. 5g). Overall, our data indicate the existence
of a causal link between the expression of the CDA and
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Fig. 5 CDA and MAPT levels are negatively correlated in cancer. Scatterplots showing the Pearson correlation between mRNA microarray data a–c or
mRNA sequencing data d–g for CDA and MAPT expression for a Institut Curie breast cancer cell lines (n= 34), b CCLE (Cancer Cell Line Encyclopedia)
cancer cell lines (n=967). c METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) breast cancer tissues (n= 1866), and d–g TCGA
(The Cancer Genome Atlas) four different cancer tissues. Dashed vertical lines correspond to mean CDA expression. P< 0.05 were considered statistically
signiﬁcant
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MAPT genes that could be exploited in the development of new
anti-cancer strategies.
Discussion
In this study, we demonstrate an unexpected role for the micro-
tubule-associated protein Tau in the survival of CDA-deﬁcient
cells; the concomitant depletion of both the Tau and CDA
proteins promotes genetic instability and is synthetic lethal. H2AX
phosphorylation and 53BP1 recruitment events have emerged as a
highly speciﬁc and sensitive molecular markers for the monitoring
of DNA damage initiation and repair50. In Tau-deﬁcient HeLa
cells, high levels of γ-H2AX and large numbers of 53BP1 foci were
observed, indicating an early cellular response to the induction of
double strand breaks. This ﬁnding is consistent with previous
studies showing higher levels of neuronal DNA damage in Tau
knockout (KO) mice than in controls. However, γ-H2AX events
did not accumulate in Tau KO mice under physiological condi-
tions, and were instead observed after heat stress (HS)-induced
damage11. This may reﬂect differences in the DNA damage
accumulation in neuronal and non-neuronal cells. UFBs, another
marker of genomic instability are considered normal, but their
frequency often increases in conditions of constitutive or induced
replication stress33, 34, 51. Tau depletion increased UFB prevalence
in our study. Thus, in addition to suffering DNA damage,
Tau-deﬁcient cells undergo endogenous replication challenges.
Tau bears some similarity to CDA in that deﬁciencies of either of
these proteins undermine genome integrity. A deﬁciency of both
Tau and CDA resulted in particularly high levels of γ-H2AX and
large numbers of 53BP1 foci, and a higher prevalence of UFBs.
Thus, the mechanisms underlying synthetic lethality involve
impaired DNA repair and replication processes.
Tau may be regarded as a multifunctional protein, the precise role
of which depends on its localization. In the cytoskeleton, Tau
mediates microtubule polymerization and stabilization17. Within the
nucleus, there is evidence to suggest that Tau is involved in DNA
protection and the promotion of chromosome stability11, 21, 52.
Nuclear Tau has also been localized to the ﬁbrillary component of
the nucleolus and to the NORs of acrocentric chromosomes in
human cells53, 54. By the double-ﬂuorescence labeling of BS cells
with anti-UBTF and anti-Tau-1 antibodies, we conﬁrmed that Tau
was localized in the nucleolus. During interphase, these two proteins
were distributed as small bead-like structures potentially corre-
sponding to individual transcriptional units. At the end of the G2
phase, when rDNA transcription is switched off55, UBTF and Tau
collect together at mitotic NORs.
Through its ability to bind to the transcribed and control
regions of rRNA genes, UBTF has been implicated in PIC
formation, transcription initiation, and elongation56, 57. The total
ablation of UBTF eliminates rRNA gene transcription and leads
to changes in rDNA chromatin58. As Tau and UBTF were
co-localized at nucleolar sites and Tau downregulation impaired
the recruitment of UBTF to rDNA promoter regions, it was
tempting to speculate that UBTF loss was also synthetic lethal
with CDA deﬁciency. UBTF knockdown seemed to favor DNA
damage and genomic instability59, but our data demonstrated
that UBTF downregulation was not synthetic lethal with CDA
deﬁciency.
As nucleolar regions contain rRNA genes, we propose a
putative role for Tau in rRNA synthesis. Indeed, we found that
the downregulation of Tau expression decreased levels of 45 S
pre-RNA, by affecting the recruitment of UBTF to rDNA repeats,
consistent with a role for Tau in the regulation of rRNA synthesis.
Moreover, Tau depletion markedly decreased the intracellular
concentrations of ribonucleotide monophosphates and tripho-
sphates, but not those of deoxyribonucleotides. Cytoskeletal
structures have been implicated in the regulation of metabolic
enzyme activity and microtubule depolymerization, leading to a
strong imbalance in total cell nucleotide pools60, 61. The decrease
in ribonucleotide levels in Tau-deﬁcient cells may, therefore,
result from a loss of the microtubule-associated function of Tau.
This decrease in ribonucleotide pool metabolism in Tau-deﬁcient
cells may account for their lower levels of rRNA synthesis.
The functional importance of Tau in protecting the integrity of
neuronal genomic DNA is directly linked to the capacity of this
protein to bind to DNA and form DNA-protein complexes62, 63.
In this context, we show here, for the ﬁrst time, that Tau binds
throughout the rDNA loci, with a preference for the promoter
and transcriptionally active regions. Furthermore, we demon-
strate that human rDNA repeats face endogenous replication
challenges and form R-UFBs. These results are supported by
recent data revealing that a fraction of UFBs in chicken cells are
derived from rDNA43. The high G-C content of rDNA loci might
render them prone to the formation of G-quadruplex structures,
causing fork stalling and/or arrest and a slowdown of rDNA
replication64. Furthermore, we showed that the partial inhibition
of replication with APH increased the prevalence of R-UFBs. This
ﬁnding is consistent with previous reports that exposure to APH
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Fig. 6 Schematic model of the interactions between CDA and Tau. a The simultaneous silencing of Tau and CDA increased genetic instability, as illustrated
by the increases in γ-H2AX and 53BP1 focus events and UFB frequency. The accumulation of DNA damage and replication stress led to a decrease in clonal
growth, and, thus, to cell death. b Tau downregulation affected rRNA synthesis by decreasing UBTF recruitment to rDNA promoters, thereby impairing the
transcription of rDNA. By contrast, Tau overexpression in CDA-deﬁcient cells led to an increase in rDNA transcription. Finally, Tau downregulation
decreased the size of the intracellular ribonucleotide pools, consistent with previous reports linking decreases in rRNA production to imbalances in
ribonucleotide pools
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weakens rDNA cluster stability, with these clusters behaving like
fragile sites40–42.
In BS ﬁbroblasts, HeLa cells and breast cancer cell lines and
tissues, low levels or absence of CDA were associated with higher
levels of Tau mRNA and protein, consistent with a physiological
mechanism regulating the levels of both proteins. Based on these
data, it is tempting to suggest that Tau overexpression in cells and
tissues with little or no CDA is one of the “emergency” systems
developed by cells, to protect themselves from the excessive DNA
damage and replication stress resulting from CDA loss per se.
However, this is not a general rule, as some CDA-low breast
cancer cells and tissues did not have high levels of Tau, suggesting
that there may be other mechanisms for overcoming excessive
DNA damage and replication stress. Nevertheless, a key goal in
cancer research is the discovery of new drug targets for selectively
impairing the viability of cancer cells. Our ﬁnding is, therefore, of
major interest. First, several reports have suggested that Tau levels
may have prognostic or predictive value in some cancers, due to
effects on the efﬁcacy of microtubule-targeted therapies and
patient care (reviewed in ref. 44). Second, CDA is increasingly
being seen as important, based on our ﬁnding that its deﬁciency
signiﬁcantly increased sensitivity to aminoﬂavone treatment45.
Thus, we suggest that targeting Tau in CDA-deﬁcient cells or
targeting CDA in Tau-deﬁcient cells may be a useful option,
guiding treatment choices, and increasing the efﬁcacy of targeted
therapies.
In conclusion, our results show that Tau depletion impairs the
survival of CDA-deﬁcient cells by favoring cellular DNA damage
and replication stress. Moreover, Tau depletion affects rRNA
synthesis and ribonucleotide pool balance, and undermines
the stability of rDNA loci (Fig. 6). Human rDNA loci display
greater instability in cancer and aging-related diseases41, 65, and
ribosomal RNA synthesis often increases in cancer cells66. Our
data, showing an overexpression of Tau in cancer cell lines
and tissues with little or no CDA, highlight the importance of
analyzing CDA and Tau expression levels simultaneously in
cancer tissues, as a relevant and predictive marker of suscept-
ibility to anti-cancer therapies.
Methods
Cell lines and drug treatments. BS GM08505B and HeLa cells were purchased
from Coriell Institute and ATCC, respectively. Cell lines were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% FCS.
BS-Ctrl(BLM) and BS-BLM cells were obtained by transfecting BS GM08505B cells
with the EGFP-C1 vector alone (Clontech) or with the same vector containing the
full-length BLM cDNA, respectively, using JetPEI reagent. After 48 h, transfectants
were selected on 800–1600 μg ml−1 G418 (PAA). Individual colonies were isolated
and cultured in medium containing 500 μg ml−1 G418.
BS-Ctrl(CDA) and BS-CDA cell lines were obtained by transfecting BS-Ctrl(BLM)
cells with an empty pCI-puro vector, or with the same vector containing the
full-length CDA cDNA (NM001785), using JetPEI reagent. After 48 h, selection
was carried out with 0.2 μg ml−1 puromycin (PAA) and 500 μg ml−1 G418
(Invitrogen). Individual colonies were isolated and maintained in culture with
0.1 μg ml−1 puromycin and 500 μg ml−1 G418.
HeLa-Ctrl(CDA) and HeLa-shCDA cells were obtained by transfecting cells with
an empty pGIPZ vector or with the same vector encoding a short hairpin RNA
sequence directed against CDA (Open Biosystems, clone V3LHS_369299),
respectively, with JetPEI reagent. After 48 h, transfectants were selected on
1–5 μg ml−1 puromycin (Invivogen). Individual colonies were isolated and cultured
in medium containing 1 μg ml−1 puromycin.
HeLa-Ctrl(Tau) and HeLa-shTau cells were obtained by transfecting cells with an
empty pRS vector or with the same vector encoding a short hairpin RNA sequence
directed against MAPT (Origene, TR311569), respectively, with JetPEI reagent.
After 48 h, transfectants were selected on 1–5 µg ml−1 puromycin (Invivogen).
Individual colonies were isolated and cultured in DMEM supplemented with 2 µg
ml−1 puromycin. All cell lines were routinely checked for mycoplasma infection.
Authenticity was assessed by comparing the generated short tandem repeat proﬁle
with the proﬁles present in the Deutsche Sammlung von Mikroorganismen und
Zellkulturen.
Deoxycytidine (dC, #D5412), aphidicolin (APH, #A0781), ICRF-159
(Razoxane, #R8657), hydroxyurea (HU, #H8627), actinomycin D (ActD, #A9415),
α-amanitin (α-AMA, #A2263), and camptothecin (CPT, #C9911) were purchased
from Sigma-Aldrich; THU was purchased from Calbiochem (#584223); CX-5461
(#HY-13323) was purchased from MedChem Express. Drugs were added to the cell
culture medium at the following concentrations and for the following amounts of
time: dC, 1 mM for 10 h; APH, 0.4 µM for 24 h; ICRF-159, 1 µM for 24 h; THU,
100 µM for 96 h (2 × 48 h). Drugs used for viability assays were added at various
concentrations, for 72 h.
Genome-wide shRNA screen and deep sequencing. BLM-proﬁcient and BLM-
deﬁcient cells were plated in six 150 mm plates, in triplicate (18 plates for each cell
line), and transduced at a MOI of 0.8 with pooled lentiviral supernatants from the
Open Biosystems GIPZ lentiviral human shRNAmir library (60,000 shRNAs)
obtained from the University of Massachusetts Medical School RNAi Core
Facility12. Each plate was divided into two populations: half of the cells for each
replicate were pooled (six plates) and genomic DNA was extracted (referred to as
“40 h”), whereas the other half were passaged in the 150 mm plates by four-fold
dilutions, as required, for 20 days, at which point the genomic DNA was extracted
(referred to as “20 days”). We analyzed the frequency of individual shRNAs in the
three replicates of the four populations, using 72 µg of genomic DNA as the
substrate (split into 24 tubes) for PCR ampliﬁcation (94 °C for 1 min, followed by
15 cycles of 94 °C for 1 min, 58 °C for 1 min, 72 °C for 45 s; 72 °C for 10 min) with
primers 5ʹ-GAGTTTGTTTGAATGAGGCTTCAGTAC-3ʹ and 5ʹ-
CGCGTCCTAGGTAATACGAC-3ʹ, targeting the core region of GIPZ. The
PCR product was gel-puriﬁed, and 50 ng of DNA was used as the substrate for
a second PCR ampliﬁcation (94 °C for 1 min; 12 cycles of 94 °C for 1 min, 50 °C
for 1 min, 72 °C for 45 s; 72 °C for 10 min) with indexed Illumina primers: forward
(5ʹ-CAAGCAGAAGACGGCATACGAGATNNNNNNGTGACTGGAGTTCA-
GACGTGTGCTCTTCCGATCTGAGTTTGTTTGAATGAGGCTTCAGTAC-3ʹ)
and reverse (5ʹ-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTA-
CACGACGCTCTTCCGATCTTACATCTGTGGCTTCACTA-
CATCTGTGGCTTCACT-3ʹ). The PCR product was puriﬁed with a Qiagen kit,
subjected to quality control and sequenced on the Hiseq Illumina platform. Overall,
678 million sequences aligned with the ENSEMBL v70 transcripts by Bowtie were
analyzed by DESeq to identify shRNAs speciﬁcally depleted during the growth of
the BLM-deﬁcient cells. We rejected shRNAs that were highly toxic to the BLM-
complemented cells (decreasing their viability by more than 50%). Hits were
selected on the basis of their relative abundance, which was signiﬁcantly lower
20 days after infection than before transfection in BLM-deﬁcient cells (at least
10-fold) but not in BLM-complemented cells.
Transcriptomic analysis. The analysis was performed on BS-Ctrl(BLM) and BS-
BLM cells7. For each cell line, three independent total RNA samples were extracted
using the RNeasy system (Qiagen). Fragmented biotinylated antisense RNA was
generated and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.
After hybridization, arrays were scanned following guidelines from Affymetrix
(http://www.affymetrix.com). These arrays contain ∼54,000 probesets, representing
∼47,000 transcripts. Data were input into R and normalized with the robust
multiarray average expression measure67. Differential expression was then assessed
with a linear model and the Bioconductor limma package68. Differentially
expressed genes were identiﬁed on the basis of a |fold change|≥ 1.5 and P< 0.05.
Transfection with siRNA and colony formation assay. Cells were transfected
with a pool of four siRNAs speciﬁc for MAPT, UBTF, CDA or BLM (ON-TAR-
GETplus SMART-pool, Dharmacon) or negative control siRNAs (ON-TARGET-
plus siCONTROL Non Targeting Pool, Dharmacon), in the presence of
DharmaFECT 1 (Dharmacon). We used a standard siRNA concentration of 50 nM.
The sequences of the siRNAs are provided in Supplementary Table 6. The colony
formation assays were carried out in 6-well or 12-well plates. Cells were counted
and used to seed plates in a serial dilution series, in at least triplicate. After 7 and
10 days of growth for HeLa and BS cells, respectively, colonies were ﬁxed and
stained with crystal violet. Colonies were scored with ImageJ. Only experiments
giving a linear correlation between the different dilutions were considered. Colony-
forming efﬁciency was estimated by dividing the number of colony-forming units
by the number of cells plated.
Immunoblotting. Proteins were isolated in lysis buffer (8 M urea, 50 mM Tris-HCl,
pH 7.5, and 150 mM β-mercaptoethanol), separated by electrophoresis in 4–12%
Bis-Tris pre-cast gels (NuPAGE Novex, Life Technologies), and blotted onto
polyvinylidene ﬂuoride membranes, which were then incubated with appropriate
primary and secondary antibodies. Bands were visualized by chemiluminescence
(Clarity Western ECL Substrate, Bio-Rad) with a ChemiDoc XRS+Molecular
Imager and Image Lab software. Uncropped immunoblots are presented in
Supplementary Fig. 5. The following antibodies were used for detection: mouse
anti-Tau-5 (#ab80579, Abcam, dilution 1:1000), mouse anti-Tau-1 (clone PC1C6,
#MAB3420, Millipore, dilution 1:1000), rabbit anti-CDA (#ab56053, Abcam,
dilution 1:500), rabbit anti-BLM (#ab2179, Abcam, dilution 1:5000), rabbit
anti-UBTF (#sc-9131, H-300, Santa Cruz, dilution 1:500), rabbit anti-γH2AX
(S139) (#2577, Cell Signaling, dilution 1:500), mouse anti-GAPDH (#G8795,
Sigma-Aldrich, dilution 1:10,000), rabbit anti-β-actin (#A2066, Sigma-Aldrich,
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dilution 1:10,000), horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG
(#sc-2054, Santa Cruz, dilution 1:5000), and HRP-conjugated goat anti-mouse IgG
(#sc-2055, Santa Cruz, dilution 1:5000).
Reverse transcription and real-time quantitative PCR. Total RNA was extracted
with the NucleoSpin RNA kit (Macherey-Nagel). RNA quality was assessed with a
NanoDrop 2000 spectrophotometer, and cDNAs were synthesized with the iScript
Advanced cDNA synthesis kit (Bio-Rad) and 1 μg of RNA. Real-time PCR was
performed with the cDNA template (1/10 dilution), iQ SYBR Green Supermix
(Bio-Rad), and 300 nM forward and reverse primers. Ampliﬁcation was performed
with the CFX96 detection system (Bio-Rad). The relative quantities of the MAPT,
CDA and BLM cDNAs were normalized against three reference genes (B2M,
β-actin and TBP). The primer sequences are provided in Supplementary Table 6.
Antibodies and immunoﬂuorescence microscopy. The primary antibodies and
dilutions used were: mouse anti-Tau-1 (PC1C6, #MAB3420, Millipore, dilution
1:500); rabbit anti-Tau (phospho Thr231) (#ab195739, Abcam, dilution 1:500);
rabbit anti-Tau (phosphor Ser396) (#ab109390, Abcam, dilution 1:1000); rabbit
anti-UBTF (H-300, #sc-9131, Santa Cruz, dilution 1:100); mouse anti-UBTF (F-9,
#sc-13125, Santa Cruz, dilution 1:100); rabbit anti-PICH (#H00054821-D01P,
Abnova, dilution 1:150); mouse anti-PICH (3F12-2B10, #H00054821-M01,
Abnova, dilution 1:100); rabbit anti-FANCD2 (#NB100-182, Novus Biologicals,
dilution 1:200); human anti-CREST (#15-234-0001, Antibodies Online GmbH,
dilution 1:100); rabbit anti-γH2AX (#39117, Active Motif, dilution 1:500); mouse
anti-53BP1 (clone BP13, #MAB3802, Millipore, dilution 1:500). The secondary
antibodies and dilutions used were: goat anti-rabbit Alexa Fluor 555, 1:500; goat
anti-mouse Alexa Fluor 488, 1:500; goat anti-human Alexa Fluor 633, 1:500; goat
anti-rabbit Alexa Fluor 488, 1:500. For Tau-1, PICH, CREST, UBTF and FANCD2
immunostainings, cells grown on coverslips were ﬁxed with 4% paraformaldehyde,
permeabilized with 0.5% Triton X-100 and blocked by incubation with 5% bovine
serum albumin. For γH2AX and 53BP1 immunostaining, cells grown on coverslips
were ﬁrst treated with cytoskeletal buffer (CSK, 100 mM NaCl, 300 mM sucrose,
3 mM MgCl2, 10 mM Hepes pH 6.7, and 0.5% Triton X-100), and then ﬁxed with
4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and blocked by
incubation with 5% bovine serum albumin/Tween 0.1%. Immunoﬂuorescence
staining was carried out by incubating with primary antibodies, followed by
secondary antibodies. Coverslips were mounted on glass slides in Prolong Gold
antifade reagent containing DAPI (Life Technologies). Images were captured with a
3-D imaging system consisting of a Leica DM RXA microscope equipped with a
piezoelectric translator (PIFOC; PI) using a×100 or ×63 objective, and were
collected as a stack of 0.2 µm increments on the z-axis (Metamorph software;
Molecular Devices). ND_Saﬁr software was used for noise reduction69. Images are
presented as maximum intensity projections, generated with ImageJ software, from
stacks deconvolved with an extension of Metamorph software. γ-H2AX and 53BP1
foci per nucleus were counted by a customized macro using a semi-automated
procedure, as follows: the nucleus stack was ﬁrst smoothed using a median ﬁlter
(radius 5), the user deﬁned an intensity value as a threshold (one value for all
experiments); a mask was then generated and transferred onto the stack of foci so
that only foci in nuclei were analyzed. A top-hat ﬁlter was applied to the result to
eliminate local background and facilitate the segmentation process, based on a
simple threshold (user deﬁned value). Finally, the macro counted and characterized
foci. At least 400 nuclei were analyzed for each condition.
Chromatin immunoprecipitation. Cells were cross-linked by incubation with
0.75% formaldehyde at room temperature for 10 min, with quenching in glycine to
a ﬁnal concentration of 0.125M for 5 min. Cells were then collected, washed twice
with ice-cold 1×phosphate-buffered saline, and resuspended in RIPA buffer. Cells
were incubated on ice for 10 min and chromatin was sonicated with a Bioruptor
Pico (Diagenode) for 10 cycles (BS and HEK-293T cells), or 20 cycles (HeLa cells),
to obtain an average DNA fragment size of 200–1000 bp. The resulting lysate was
precleared by centrifugation for 10 min at 4 °C and stored at −80 °C for immu-
noprecipitation. We cross-linked 10 µg of anti-Tau-1, 3 µg of anti-UBTF, and 5 µg
of anti-IgG antibodies to the beads (Dynabeads Protein G) by incubation with
dimethyl pimelimidate (DMP, 13 mgml−1) for 30 min, and then incubated the
beads with chromatin lysate overnight at 4 °C, with rotation. The beads were
sequentially washed with 500 μl each of the following buffers: low-salt wash buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, 150 mM NaCl),
high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl
pH 8, 500 mM NaCl), and LiCl wash buffer (0.25 mM LiCl, 1% Nonidet P-40, 1%
sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8). The immune com-
plexes were eluted with 150 μl of freshly prepared elution buffer (1% SDS, 100 mM
NaHCO3). The cross-linking reaction was reversed by overnight incubation of the
eluents with 0.2 M NaCl at 65 °C, and the DNA was then treated with 1 μg of each
RNase A and proteinase K, and recovered with a PCR puriﬁcation kit (Qiagen).
Approximately 5% of the bound DNA fraction was used for quantitative PCR.
All primers used in qPCR analyses are detailed in Supplementary Table 6. Data
were normalized against non-speciﬁc genomic DNA and relative to IgG.
Cell viability assay. Cells were plated at a density of 2×103 per well in 96-well
microplates, in triplicate. After 24 h, cells were left untreated or treated with various
doses of each drug. After 72 h, cell viability was assessed with 3-(4,5-dimethyl-2-
thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide (MTT; Life Technologies).
Nucleotide determinations. The determination of ribonucleotide triphosphates
(NTP: ATP, UTP, GTP, and CTP), deoxyribonucleotide triphosphates (dNTP:
dATP, dCTP, dGTP, and dTTP), ribonucleotide monophosphates (NMP: AMP,
UMP, GMP, and CMP), and deoxyribonucleotide monophosphates (dNMP:
dAMP, dCMP, dGMP, and dTMP) was performed with a published method based
on an online extraction coupled with LC–MS/MS70. Brieﬂy, online extraction was
performed with an Oasis-WAX column (3.9 × 20 mm; 30 µm—Waters), followed
by a Hypercarb analytical column (2.1 × 100 mm; 5 µm—ThermoScientiﬁc) for the
separation of the compounds. Gradient elution was performed with a constant
proportion of NH4OH (0.25%—pH 10), varying proportions of water and
acetonitrile. An electrospray ionization source was used and the positive mode
was selected for detection of the compounds. For each ribonucleotide and
deoxyribonucleotide, the peak surface area ratio was determined between the
endogenous nucleotide and the corresponding labeled nucleotide used as an
internal standard (adenosine-13C10,15N5 5ʹ-triphosphate (ATP13C,15N), uridine-
13C9,15N2 5ʹ-triphosphate (UTP13C,15N), thymidine-13C10,15N2 5ʹ-triphosphate
(TTP13C,15N), cytidine-15N3 5ʹ-triphosphate (CTP15N), guanosine-13C10 5ʹ-tripho-
sphate (GTP13C), adenosine-13C10,15N5 5ʹ-monophosphate (AMP13C,15N), thymi-
dine-13C10,15N2 5ʹ-monophosphate (TMP13C,15N), uridine-15N2 5ʹ-monophosphate
(UMP15N), cytidine-15N3 5ʹ-monophosphate (CMP15N), guanosine-13C10,15N5
5ʹ-monophosphate (GMP13C,15N), 2ʹ-deoxyadenosine-13C10,15N5 5ʹ-triphosphate
(dATP13C,15N), 2ʹ-deoxycytidine-13C9,15N3 5ʹ-triphosphate (dCTP13C,15N), 2ʹ-
deoxyguanosine-13C10,15N5 5ʹ-triphosphate (dGTP13C,15N), 2ʹ-deoxyadenosine-
13C10,15N5 5ʹ-monophosphate (dAMP13C,15N), 2ʹ-deoxycytidine-13C9,15N3
5ʹ-monophosphate (dCMP13C,15N), 2ʹ-deoxyguanosine-13C10,15N5 5ʹ-monopho-
sphate (dGMP13C,15N)) making it possible to take into account the matrix effect for
each compound. Cell extracts were prepared as follows: the cells were washed with
phosphate-buffered saline and subjected to extraction in 3 ml of a mixture of
methanol and water (70/30; v/v). The resulting extract was transferred to a tube,
shaken for 5 min, and stored at −80 °C until analysis. On the day of analysis, a
mixture containing all the internal standards was added to each sample, and
the samples were then vortexed and centrifuged for 10 min at 13,000 × g. The
supernatant was then evaporated off under nitrogen at 37 °C and the dry residue
was resuspended just before injection into the LC–MS/MS apparatus.
Statistics. At least three independent experiments were carried out to generate
each data set. The statistical signiﬁcance of differences in colony formation and
mRNA levels was determined in two-tailed paired t-tests. Differences in ultraﬁne
anaphase bridge frequencies were assessed in two-tailed unpaired t-tests. Pearson
correlation analysis was used to assess the association between CDA and MAPT
transcript levels. P-values for nucleotide pool measurements were obtained in
Mann–Whitney tests, with values of P< 0.05 considered signiﬁcant.
Data availability. Raw and normalized sequencing (synthetic lethality screen) and
transcriptomic data are available from the Institut Curie microarray dataset
repository (http://microarrays.curie.fr/; Direct links: http://microarrays.curie.fr/
publications/ UMR3348/shRNA-based-bloom-syndrome-cells/ and http://
microarrays.curie.fr/publications /UMR3348/pyrimidine-bloom-syndrome/).
MAPT and CDA expression levels were extracted from a collection of 34 human
breast tumor cell lines (mostly from ATCC) established at the Translational
Research Department of Institut Curie45, from the Gene Expression Omnibus
(GEO) dataset no. GSE5450222, from the Cancer Cell Line Encyclopedia (CCLE)46,
from the European Genome-Phenome Archive dataset no. EGAS0000000008347
and from the TCGA portal55, 56.
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